Early Advantage Fund Invests £75,000 In Abgentis
A company creating new treatments for life-threatening and drug-resistant bacterial infections has received a cash…read more
Abgentis’ goal is to provide a new broad-spectrum IV/oral antibacterial to treat acute and chronic, life-threatening and drug-resistant infections. Based on a previously marketed but uncompetitive compound, Abgentis’ “fast-follower” programme will deploy unique insight into the structure-activity relationships, microbiology, pharmacology and efficacy of antibacterial DNA supercoiling inhibitors to rapidly re-engineer and optimise, to create an internationally competitive product. The keys to market penetration are the IV and oral bioavailability (enabling step-down therapy), the spectrum of activity including both Gram+ve and Gram-ve pathogens and the ultra-low spontaneous resistance frequency.
Associated Fund Early Advantage Fund
Sector Medical / Biotechnology
GYR12, Abgentis' lead novobiocin analogue, in combination with colistin, is effective against colistin-resistant strains...read more
Novel antibacterial programmes developed under the leadership of Lloyd Czaplewski when he was at...read more